US Patent 11155630 Therapeutic antibodies and their uses

Patent 11155630 was granted and assigned to Pfizer on October, 2021 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

Pfizer

Current Assignee

Pfizer

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11155630

Date of Patent

October 26, 2021

Patent Application Number

20201221

Date Filed

December 21, 2020

Patent Citations Received

‌

US Patent 11912776 Chimeric antigen receptors targeting B-cell maturation antigen

Patent abstract

The present invention relates to bispecific antibodies that specific bind to BCMA (B-Cell Maturation Antigen) and CD3 (Cluster of Differentiation 3). Method of making the bispecific antibodies and method of using the bispecific antibodies for the treatment of multiple myeloma are also provided.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11155630 Therapeutic antibodies and their uses

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API